IMR Press / CEOG / Volume 38 / Issue 3 / pii/1630542838283-322043118

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients
Show Less
1 Technological Educational Institute of Athens, School of Midwifery, Athens
2 Family Planning Unit, 2nd Department of Obstetrics and Gynecology, Aretaieio Hospital, University of Athens Medical School, Athens
3 LITO Hospital, department of Gynecological Oncology, Athens
4 Department of Obstetrics and Gynecology, Tzaneio Hospital, Piraeus (Greece)
Clin. Exp. Obstet. Gynecol. 2011, 38(3), 225–227;
Published: 10 September 2011
Abstract

The investigation of potential predisposing factors of breast cancer, a disease accounting for almost one-third of malignancies in women, is necessary in order to reduce the incidence. Materials and Method: We interviewed 405 female patients who had been diagnosed with breast cancer and who also reported having used oral contraceptive pills before. They were categorized into two groups (group A < 7 years OC use and group B > 7 years OC use). Results: Statistical analysis revealed a small (p < 0.02) but significant increased risk of the disease to BRCA mutation carriers, as well as to the women with a significant medical or family history of breast, ovarian or colon cancer who had also previously used oral contraceptive pills for more than seven years. Discussion: Breast cancer seems to be positively dependent on prolonged oral contraceptive use. Conclusion: More research is needed to establish the hypothesis that the human genome is vulnerable to oral contraceptives.
Keywords
Breast cancer
Risk factor
Oral contraceptives
BRCA mutation carriers
Prolonged use
Share
Back to top